USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
USANA Health Sciences reported fiscal Q1 2026 net sales of $250.2 million, essentially flat year over year, while profitability declined. Net earnings were $7.5 million versus $9.4 million a year ago, and diluted EPS fell to $0.41 from $0.49. Adjusted diluted EPS was $0.61 compared with $0.73, and Adjusted EBITDA was $28.4 million versus $29.8 million.
The Core Nutritional segment generated $204 million in net sales, down 3% year over year but up 7% sequentially, with 404,000 active customers, a 12% annual decline yet 4% sequential growth. Hiya posted $32 million in net sales, down 13% year over year, while Rise Wellness net sales surged to $14 million, up 741% year over year.
USANA ended the quarter with $163 million in cash and $14 million of debt. Management reiterated full‑year 2026 guidance, including consolidated net sales of $925 million to $1.0 billion, net earnings of $20 million to $27 million, diluted EPS of $1.11 to $1.45, and Adjusted EBITDA of $101 million to $109 million.
USANA Health Sciences director Timothy E. Wood reported routine equity compensation activity involving restricted stock units. On April 23, 2026, 1,057 restricted stock units converted into 1,057 shares of common stock, reflecting a derivative exercise with no cash purchase.
On the same date, 264 common shares were disposed of at $19.24 per share as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold in the open market. Following these transactions, Wood directly held 10,613 shares of USANA common stock.
USANA Health Sciences director Frederic J Winssinger exercised restricted stock units into common stock, acquiring 1,057 shares. Following this transaction, he directly holds 8,101 shares of USANA common stock. Each restricted stock unit represents a contingent right to receive one share, with vesting in 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director J. Scott Nixon reported exercising 1,057 restricted stock units into an equal number of USANA common shares on April 23, 2026. Following this transaction, he directly holds 9,813 shares of common stock. Each restricted stock unit represented a right to receive one USANA share, and the units vested in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Gilbert A. Fuller exercised 1,057 restricted stock units into common stock. On April 23, 2026, 1,057 RSUs converted into 1,057 shares of USANA common stock at a stated price of $0.00 per share. After the transaction, he directly holds 1,057 common shares and no remaining RSUs under this grant.
Each restricted stock unit represented a contingent right to receive one share of common stock, with the grant vesting in 25% increments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Peggie Pelosi reported routine equity compensation activity involving restricted stock units and common shares. On April 23, 2026, 1,057 restricted stock units were exercised into 1,057 shares of common stock at a conversion price of $0.00 per share. To cover tax obligations, 668 common shares were disposed of at $19.24 per share as a tax-withholding disposition, rather than an open-market sale. After these transactions, Pelosi directly held 5,364 shares of USANA common stock.
USANA Health Sciences director John Turman Fleming exercised 1,057 Restricted Stock Units into Common Stock on April 23, 2026. The RSUs converted into 1,057 shares of USANA common stock, increasing his directly held position to 6,680 shares after the transaction. Each RSU represented a contingent right to receive one share of common stock, with this grant vesting in 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Xia Ding reported routine equity compensation activity involving restricted stock units. On April 23, 2026, 1,057 restricted stock units converted into common stock, reflecting a derivative exercise tied to prior awards. To cover tax obligations, 391 shares of common stock were withheld and disposed of at $19.24 per share as a tax-withholding transaction, not an open-market sale. Following these transactions, Xia Ding directly held 7,641 shares of USANA common stock.
USANA Health Sciences is holding a virtual Annual Meeting on May 20, 2026, at 11:00 AM MDT to let shareholders vote online. Holders of 18,456,935 common shares as of March 16, 2026 can participate using a 16-digit control number.
Shareholders will elect eight directors, ratify KPMG LLP as independent auditor for Fiscal Year 2026, and cast an advisory vote on executive compensation. The Board recommends voting FOR all three items and highlights strong governance practices, including a majority of independent directors, a Lead Independent Director, stock ownership guidelines, a clawback policy, and prohibitions on pledging or hedging USANA stock.